Massachusetts General Hospital
Harvard Medical School
Alzheimer’s disease has traditionally been viewed as a proteinopathy. However, recent evidence highlights circuit disruptions as part of the disease progression. We implement optogenetics to control activity within neuronal circuits and imaging with multiphoton microscopy to monitor circuit dynamics with the aim to dissect the role neural activity plays in onset and development of Alzheimer’s disease.
In an attempt to prevent and/or reverse the disorder, we have partnered with industry leaders to study the effects and mechanisms of action of Alzheimer’s therapeutics, such as anti-Abeta immunotherapy, aducanumab, and the novel multimodal botanical extract DA-9803. We strongly believe that these translational studies are important for getting effective therapies to patients.